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Introduction
Apart atrial and ventricular ectopic beats, atrial
fibrillation (AF) is the most frequently occurring cardiac
rhythm disturbance. Its prevalence in the population
increases with age: it is 2 to 3 per 1000 between 25 and
35 years, 30 to 40 per 1000 between 50 and 64 years,
and 50 to 90 per 1000 between 62 and 90 years [1]. In
the Framingham study, in a 22 to 30-year follow-up, the
incidence of AF was observed to increase progressively
with age, with a modest male predominance, and overall
the chance of developing this arrhythmia over two
decades was 2% [2].
The social costs caused by AF are relevant: in the
United States AF caused far more hospital admissions
than any other arrhythmia, accounting for almost a
million days spent in hospital per year [3].
AF may occur in different clinical forms, referred as
paroxysmal, persistent and permanent AF (Table 1) [4, 5].
For the treatment of AF three main goals have to be
considered: 1) maintenance of sinus rhythm by
preventing AF recurrences; 2) rate control during AF;
3) prevention of AF-related thromboembolic risk.
For the first two goals both pharmacological and non
pharmacological treatments can be used, alone or in
combination. The choice about the most appropriate
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Summary. - At present the approach to atrial fibrillation treatment is based on the electrophysiological
patterns of atrial fibrillation (on the basis of multiple intra-atrial recordings or sophisticated new mapping
techniques) only in a restricted minority of patients, those who are candidate to ablation of the substrate and/or
of the triggers. Atrial fibrillation  has a broad spectrum of clinical presentations and a heterogeneous
electrophysiological pattern. The treatment of this arrhythmia, both with drugs and non pharmacological
treatments, has been based, classically, on empirical basis and on a clinically-guided staged-approach. The
limitations of pharmacological treatment led in recent years to the development of a wide spectrum of non
pharmacological treatments. This implies a change in the approach to atrial fibrillation and the need to identify
potentially ideal candidates to complex  and  expensive treatments. In this view it is currently under investigation
the possibility to identify potential responders to a definitive treatment or a combination of treatments (both
pharmacological and non-pharmacological) on the basis of the electrophysiological pattern.
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Riassunto (Trattamento dei pazienti con fibrillazione atriale: opzioni terapeutiche e ruolo di un approccio
elettrofisiologico). - Attualmente, il trattamento della fibrillazione atriale si basa sull’analisi del pattern
elettrofisiologico solo in una ristretta popolazione di pazienti, i candidati a procedure di ablazione del substrato
e/o dei trigger. La fibrillazione atriale ha un ampio spettro di presentazioni cliniche e un eterogeneo pattern
elettrofisiologico. Il trattamento farmacologico e non farmacologico di questa aritmia è stato impostato
classicamente su basi empiriche e su un approccio clinico a gradini. La limitata efficacia dei trattamenti
farmacologici ha condotto, negli ultimi anni, allo sviluppo di una ampia gamma di trattamenti non farmacologici.
Tutto ciò implica un cambiamento nell’approccio alla fibrillazione atriale e la necessità di identificare a priori i
potenziali responder a trattamenti complessi e costosi. In quest’ottica è attualmente oggetto di studio la possibilità
di identificare, sulla base del pattern elettrofisiologico, i potenziali responder a un trattamento curativo o a una
combinazione di trattamenti (farmacologici e non farmacologici).
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treatment depends on several factors including arrhythmia
characteristics, AF related symptoms, impairment of
quality of life due to AF and concomitant heart disease. In
Table 1 a summary of currently available therapeutic
options is shown. Persistent AF may be a difficult field for
patients’ management. Indeed, the decision to try to
maintain sinus rhythm or, alternatively, to limit treatment
to rate control and prevention of thromboembolic risk,
should be individualised for each patient, trying to assess
the risk-benefit ratio in each clinical case.
The complexity of AF electrophysiology:
its heterogeneity, dynamics and plasticity
AF is a heterogeneous disease and its heterogeneity is
related to its clinical presentation (paroxysmal, persistent,
permanent), its clinical evolution (ranging from a single
episode to frequently recurrent episodes evolving to
persistent AF) and its clinical relevance (ranging from none
to acute hemodynamic impairment or development of
tachycardiomyopathy with congestive heart failure).
Heterogeneity involves also the electrophysiological
pattern. In order to analyse the degree of electrical
organisation of AF, this arrhythmia was initially divided,
on the basis of the pattern at surface electrocardiogram,
into “coarse” and “fine” AF [6, 7]. Later Wells et al. [8] in
a study based on recordings from unipolar epicardial
electrodes positioned surgically in the right atrium,
described 4 patterns of AF, with a variable degree of
organisation of the signals and with possible transitions
from one pattern to another even in a short time.
According to these preliminary observations, AF in
humans resulted to have a heterogeneous patterns among
different patients or ad seriatim in the same patient. A
series of more accurate mapping studies in humans [9]
showed that AF is sustained by different patterns of atrial
activation correspondent to different types of re-entry
or to focal activation [10].
A series of studies analysed intra-atrial recordings during
AF for evaluating the patterns of spontaneous or
pharmacologically induced AF termination [11-15] or the
pattern of spontaneous or electrically induced AF onset [16].
Heterogeneity increases when mapping at multiple
sites is performed [9, 17] and this finding may offer some
insights into AF electrophysiological mechanisms.
Indeed, multiple types of circuit may sustain AF
perpetuation [10]: random reentry, leading circle reentry
or repetitive focal activation [18]. The key question is
how to assess easily, in the single patient, the electro-
physiological mechanism sustaining AF persistence in
order to guide the treatment (drugs, ablation, electrical
treatment) with the aim to improve the efficacy in AF
management.
Apart heterogeneity, also dynamics characterises the
electrophysiological characteristics of AF with changes of
its patterns occurring in a short time. Evaluation of atrial
endocardial recordings shows that intracardiac organisation
exists at AF onset but may evolve into new activation
patterns in few beats, with arrhythmia perpetuation [16],
and that the atrial cycles lengthens before termination in
self-terminating paroxysmal AF [13].
Other changes in the electrophysiological pattern of
AF occur at long term and this phenomenon is the
expression of the plasticity of AF. The term “remodeling”
Table 1. - Options for AF treatment in different types of AF. (Modified from [3]).
Paroxysmal AF Persistent AF Permanent AF
Arrhythmia characteristics Terminates spontaneously Will not terminate Will not terminate
spontaneously but spontaneously, cannot be
can be converted to SR converted to SR
Short-term treatment goal Rate control Cardioversion to SR Rate control
Rate control
Long-term treatment goal Prophylaxis of AF recurrences Prophylaxis of AF Rate control
recurrences
Rate control
Potential treatments AA drugs for prophylaxis AA drugs for conversion AA drugs for rate control
Preventive pacing External CV AV node modification
Ablation Internal CV AV node ablation + pacing
Atrial defibrillator Atrial defibrillator Ablation
AA drugs for rate control
AA drugs for prophylaxis
Preventive pacing
Pacing to stop AF
AF: atrial fibrillation; AA drugs: antiarrhythmic drugs; AV: atrioventricular; CV: cardioversion; SR: sinus rhythm.
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was initially introduced by Allessie’s group [19] to indicate
long term changes in atrial refractoriness resulting from
prolonged changes in atrial rate. Today, remodeling
indicates a complex series of electrophysiological and
structural changes (Table 2) that induce a vicious circle
leading to perpetuation of the arrhythmia (“AF begets
AF”) [20]. This phenomenon has been confirmed in
humans [21, 22]. The electrophysiological changes are
potentially reversible with restoration and maintenance
of sinus rhythm but it is unknown how long the complete
spectrum of electrophysiological/structural changes is
fully reversible. Remodeling influences deeply the efficacy
of our approach to AF management and improved
knowledge of this complex phenomenon may provide new
targets for prevention and treatment of AF [20].
The possibility to guide the treatment of AF on the
basis of trigger/initiation pattern is critically challenged
by the observation of the AF therapy trial, where a
diagnostic pacemaker programmed at low rate was used
to assess the pattern of onset of paroxysmal AF. In this
study [23] multiple triggers were identified with
important inter-individual and intra-individual variability
of the onset pattern (a mean of 4.1 ± 2.5 different triggers
per patient were observed).
Atrial fibrillation termination versus prevention
of recurrences by antiarrhythmic drugs
Different antiarrhythmic agents, with disparate
electrophysiologic effects, have been used for terminating AF
episodes or for preventing AF recurrences [24-30]. For
most patients it is prevention of AF recurrences rather
than restoration of sinus rhythm that is the most difficult
problem to solve.
A series of antiarrhythmic agents was demonstrated
to be highly effective in terminating recent onset AF,
with class 1C agents being the most effective [31, 32].
In contrast with the high efficacy in recent-onset AF, the
results obtained in prophylaxis of AF recurrences are
scanty [20, 33-35].
Different experimental models have been adopted
for studying the effects of antiarrhythmic drugs in
terminating experimental AF. According to the leading
circle model [20] and the multiple wavelet theory [36],
termination of AF was initially considered to be related
to the ability to increase the wavelength of reentry
circuits, by an increase in the size of individual reentry
circuits and a decrease in their number. According to
this hypothesis, when the number of reentry circuits is
critically low, fibrillation can’t maintain itself and stops
by block in a single macroreentry circuit, by short-
circuiting of reentry or by collision of wave fronts [36].
This hypothesis was recently questioned by new
experimental observations of the same group [37].
Pharmacological cardioversion of AF with a series of
class I or class III antiarrhythmic agents could not be
explained by prolongation of the wavelength, meanwhile
it was possible to interpret the data on the basis of a
widening of the temporal excitable gap [37].
Reduction of inhomogeneity in atrial refractoriness
is another important factor involved in the pharmacological
effects leading to arrhythmia termination. Antiarrhythmic
agents may exert frequency-dependent effects on
conduction and refractoriness: flecainide and propafenone
cause a rate-dependent increase in refractoriness, whereas
sotalol has a reverse-rate dependent effect on refractoriness.
It is of interest to consider that the efficacies of these drugs
were correlated to the changes in refractoriness and
wavelength produced at the rapid rates of AF and sotalol
resulted less effective than flecainide and propafenone
[36]. These experimental evidences suggest that class
III antiarrhythmic agents with reverse rate-dependent
effect on refractoriness would be of limited efficacy in
terminating AF and this is in accordance with clinical
Table 2. - Time course of atrial alectrical remodeling and mechanisms involved
Time Remodeling Mechanism
Short-term (s/min) Metabolic Ionic gradient fluxes
Ion pump activities
Phosphorilation of ion channels
Medium-term (hours/days) Electrical Altered gene expression
Altered protein synthesis
Altered channel assembly
Long-term (weeks) Contractile Hibernation
Stunning
Very long-term (months/years) Anatomical Irreversible structural damage
Fibrosis
Fatty degeneration
Atrial dilation
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observations [32]. The mechanism of AF prevention is
partly different from arrhythmia termination; as known,
atrial premature beats initiate AF by blocking in an area of
longer refractoriness, resulting in a single macroreentry
circuit followed by multiple focal zones of reentry causing
AF [36]. The ability to lengthen atrial refractoriness during
sinus rhythm may prevent atrial premature beats from
initiating AF. Therefore, while class III antiarrhythmic
agents with reverse rate-dependence may have limited
efficacy in terminating AF, they may nonetheless be
effective in preventing arrhythmia recurrences due to
premature beats during sinus rhythm at normal slow rate.
Indeed, a recent prospective trial [38] showed that
amiodarone is more effective than sotalol or propafenone
for the preventions of AF.
Maintenance of sinus rhythm versus control
of ventricular response
In patients with AF, restoration of sinus rhythm by
electrical or pharmacological cardioversion may eliminate
palpitations, fatigue and dyspnea, may prevent left
ventricular dysfunction and may significantly reduce
thromboembolic complications. Unfortunately, because of
the high recurrence rate, only 30% of the patients, without
antiarrhythmic drug prophylaxis, maintain sinus rhythm
for 6 months or more [39]. Therefore, attempts to maintain
sinus rhythm by pharmacological prophylaxis of
arrhythmia recurrences is required. Antiarrhythmic drugs
may cause proarrhythmic effects or other adverse effects
and for this reason this prophylactic strategy has to be
considered as an alternative to another therapeutic strategy
which is based only on ventricular rate control by
appropriate drugs associated with antithromboembolic
prophylaxis. Advantages and disadvantages of each
therapeutic option are reported in Table 3.
The impact of these two different approaches to AF
management is currently under evaluation in a controlled
trial, named AFFIRM (AF follow-up investigation of
rhythm management) [40].
Non-pharmacological treatments for AF
The limited efficacy of antiarrhythmic agents and
the evidence that adverse effects including proarrhythmic
effects may be caused by antiarrhythmic treatment led
to the development of non-pharmacological treatments,
whose cost-benefit profile is in most cases still under
evaluation. Non pharmacological treatments developed
in recent years for management of AF include atrial
pacing, internal atrial cardioversion and catheter or
surgical ablation procedures.
Atrial pacing for AF prevention
The effects of conventional atrial pacing in
preventing AF recurrences need to be evaluated in
patients with sick sinus syndrome at low risk of AF, in
patients with brady-tachy syndrome at high risk of AF,
and in patients with paroxysmal AF without significant
bradycardia.
In the last 10 years a series of retrospective studies
[41-46] showed that there was a higher risk of developing
AF in patients with sick sinus syndrome paced in the
VVI mode than in those paced in AAI or DDD. Sgarbossa
et al. [47] in a retrospective study found that VVI pacing
was associated to risk of developing chronic AF in
patients with preimplant AF but not in those without it.
The prospective randomised study reported by Andersen
et al. [48], involving 225 patients, showed that more
patients (23%) randomised to VVI pacing developed AF
over a 40-month period than patients randomised to AAI
pacing (14%). This difference, however, did not reach
statistical significance.
In patients with sick sinus syndrome with an high
risk of AF (brady-tachy syndrome) DDDR pacing
achieved a significant reduction of AF episodes both in
comparison to baseline and to DDD pacing [49]. In
patients with AF, without symptomatic bradycardia, the
possible mechanisms supporting a beneficial effect of
pacing in AF prevention are: 1) prevention of bradycardia,
Table 3. - Alternative therapeutic strategies for atrial fibrillation management: advantages and disadvantages of
each therapeutic option
Maintenance  of sinus rhythm Control of ventricular rate
by antiarrhythmic drugs + antithromboembolic prophylaxis
Advantages Advantages
Better hemodynamics “Natural history”
Reduction in thromboembolic risk Absence of relevant proarrhythmic effects
Disadvantages Disadvantages
Risk of drug-related proarrhythmic effects Worse hemodynamics
Risk of other drug-related adverse effects Hemorragic risk due to anticoagulants
Need for repeated cardioversions Residual embolic risk
(if partial efficacy)
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2) better adaptation of heart rate to exercise, 3) overdrive
suppression of ectopic beats, 4) shortening of prolonged
interatrial conduction due to atrial ectopic beats.
The ways to positively influence the risk of AF are
related to: 1) pacing mode, 2) pacing rate, 3) pacing site
(single site or multisite), 4) use of novel, dedicated pacing
algorithms - consistent atrial pacing (CAP), atrial rate
stabilization (ARS) or dynamic atrial overdrive (DAO)
- and, finally, 5) use of pacing to stop AF episodes.
A great interest was developed in recent years on the
effects of pacing site on the risk of AF. Indeed, the site of
atrial pacing can impact on the development of AF in
pacemaker patients. Multisite atrial pacing may favourably
modify the atrial electrophysiological substrate in patients
with paroxysmal AF [50, 51] or in animal studies [52].
These findings had important implications for applying,
in the clinical setting, pacing techniques aimed to reduce
inhomogeneities in atrial conduction and refractoriness
and normalise atrial activation.
The incidence of AF appears to be higher with pacing
from the right auricular lateral wall compared with
pacing from the right auricular appendage [53], whereas
pacing from the interatrial septum can reduce the
interatrial conduction time and possibly prevent AF [54].
Intra and interatrial conduction delays are frequent in
patients with AF. In this regard, right auricular appendage
pacing appears to be more effective in preventing AF in
patients with sick sinus syndrome without marked atrial
conduction delay [55].
The search for better clinical results in terms of AF
prevention led to test pacing in alternative sites (coronary
sinus, coronary sinus os, interatrial septum) or to test
dual/multi-site atrial pacing. Clinically, multisite atrial
pacing has been achieved via biatrial pacing (one lead
in the right auricular appendage and the other in the
coronary sinus to pace the left atrium [56]) or via dual-
site right atrial pacing (one lead in the appendage and
the other in the interatrial septum just outside the
coronary sinus ostium [57]). Pacing from the distal
coronary sinus [50, 51] or its ostium [58] prevents the
induction of AF by high right auricular premature
depolarisations by limiting their prematurity at the
posterior triangle of Koch and by not allowing local
conduction delay and local re-entry to occur.
At present the translation of these observations into
the clinical setting showed that multisite atrial pacing or
pacing from alternative sites was more effective than
single-site right auricular pacing when AF was associated
to bradycardia [54, 59] but disappointing results were
found in controlled studies when AF was not associated
to bradycardia [60]. This finding stresses the need for
further knowledge on the complex interaction between
atrial pacing and the electrophysiological substrate
favouring AF onset in specific subgroups of patients.
New pacing modalities for preventing AF recurrences
include special algorithms to increase the rate of atrial
pacing, thus leading to continuous overdrive pacing or
for suppressing the pauses that follow an atrial ectopic beat
[61]. These algorithms (CAP, ARS, DAO) are currently
under evaluation and preliminary data seem promising
[62]. Unfortunately the wide variability in AF onset
pattern, also in the same patient [23] create some
difficulties in identifying the most appropriate algorithm.
A new perspective of atrial pacing is related to the
possibility to capture locally the atrium by high
frequency stimulations [63]. These observations raise
the possibility in the next future of rapid termination of
AF through multi-site pacing. In this perspective, it is
really interesting to consider the preliminary experience
on the use of 50 Hz burst stimulation. In patients
implanted with a dual chamber atrial defibrillator able
to deliver antitachycardia pacing, 50 Hz bursts were able
to terminate 33% of episodes classified by the device as
AF episodes [64].
Internal atrial cardioversion
Atrial cardioversion (CV) can be performed by
delivering biphasic shocks between transvenous
catheters positioned within the cardiac chambers or great
vessels.
Low energy internal atrial CV can be performed by
two approaches: by placing the leads in right atrium (RA)
and coronary sinus (CS), or left polmonary artery, in order
to obtain defibrillating currents that preferentially
encompass the atrial tissue or by placing the leads in RA
and right ventricle (RV) with the same configuration used
for ventricular defibrillation. The efficacy for terminating
AF is very high, 92-100% for paroxysmal AF [65] and
77-100% for chronic persistent AF [66] with relatively
low energy requirements, especially when dealing with
paroxysmal AF. Delivery of shocks results in effective
CV at energies below 6-10 joule and the procedure can
be effective even when external CV has failed. Shock
induced discomfort shows wide variability from patient
to patient but the procedure can be performed without
general anaesthesia, under sedation. Nevertheless,
tolerability has to be improved by obtaining a substantial
reduction in defibrillation thresholds. Atrial defibrillation
threshold is usually evaluated in clinical studies by using
a step up protocol and this implies some approximation
in comparison with the methodology used for
defibrillation threshold evaluation in animal studies.
Apart clinical issues, atrial defibrillation threshold seems
to be dependent on some technical issues such as
electrode size [67], electrode positioning [68], electrode
coil length [69, 70]; moreover atrial defibrillation
threshold is more favourable when biphasic versus
monophasic shock waveforms are delivered, when
asymmetrical waveforms with the second phase shorter
than the first phase are used [69] and when sequential
shocks are delivered trough dual current pathways [71].
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Atrial electrophysiological substrate is obviously
important in conditioning the atrial defibrillation
threshold during internal cardioversion. In transvenous
cardioversion the atrial defibrillation threshold was
higher in chronic AF than in paroxysmal AF [72]. In a
recent study evaluating the predictors of atrial
defibrillation threshold among a series of clinical,
electrophysiological and echocardiographic parameters,
only AF duration resulted to be an independent predictor
of the atrial defibrillation threshold [73].
In an experimental model of AF, the remodeling of the
atrial electrophysiological substrate that occurred after 8
hours of pacing-induced AF was associated with a
significant increase in atrial defibrillation threshold [74].
Moreover, reverse remodeling of atrial refractoriness
following internal conversion of AF was associated wiht a
significant decrease of atrial defibrillation threshold [75].
Tolerability of shock induced discomfort is an
intriguing problem because patients perception of pain
is probably dependent on several factors: psychological
status and patient conditioning, number of shocks
delivered, energy delivered, shock waveform, leads
positioning [69, 76, 77]. A great interindividual
variability exists in shock induced discomfort and some
patients report severe discomfort even after delivery of
shocks at 0.1 joule of energy [71]. On the other hand,
our group and others [76, 77] reported the feasibility of
the procedure with no or mild sedation in a substantial
proportion of patients.
Delivery of shocks for defibrillating the atria implies
a potential risk of inducing ventricular fibrillation and
cases of ventricular fibrillation following internal atrial
CV have been reported [78]. To minimise this problem,
delivery of the shocks in synchronous with the QRS is
mandatory and moreover it’s important to avoid shock
delivery during rapid RR cycles (< 300 ms) because of
tachycardia dependent inhomogeneity of repolarisation
[79].
Following cardioversion of a chronic persistent AF,
recurrences have a typical time course, with an early or
very early phase of increased vulnerability [69]. Different
electrophysiological, structural, clinical, autonomic and
neurohormonal factors condition the risk of AF relapses
following CV, but for recurrences occurring in an early
phase (few hours) or in a very early phase (seconds,
minutes) post-cardioversion, the electrophysiological
factors may have a predominant role.
An electrical remodeling of atrial refractoriness has
been described both in animal and human studies [19]
and this phenomenon may condition an high
vulnerability to AF recurrences immediately following
CV. Immediate reinitiation of AF, defined as recurrence
within 1 minute, has been described to occur in 13-36%
of patients submitted to low energy internal atrial CV
[69] and it had a substantial impact also on initial
experiences with implantable atrial defibrillators [80].
A key point is therefore to define the effects of
antiarrhytmic agents in reducing AF recurrences at short
and long term and of pre-treatment with calcium
antagonist, to reduce electrophysiological remodeling
and, indirectly, AF recurrences. Evaluation of the effects
of antiarrythmics drugs on atrial defibrillation threshold
is at present possible for evaluating the effects of drugs
in patients submitted to low energy atrial CV [78].
Although, at present time, transvenous low energy
CV is still an investigational procedure, a widening of
indications is expected in the near future [72]. Low
energy internal CV allowed development of devices for
atrial defibrillation. The first experience on a stand-alone
atrial defibrillator was published by Wellens et al. [80]
and included in 51 patients. During the follow up 96% of
the episodes was succesfully converted to sinus rhythm
but early recurrence of AF (within 1 minute) was observed
in 27% of the episodes and in 51% of the patients, thus
supporting the need for concurrent antiarrhytmic therapy.
A dual chamber defibrillator has been also tested [64,
68]. In this system addition of an atrial lead to a
cardioverter-defibrillator allows diagnostic informations
in combination with atrial pacing capability (delivery of
different antitachycardia pacing therapies, including 50
Hz stimulation) and with possibility of R wave
synchronous shock therapy. In this system a coronary
sinus lead is not required. Mean atrial defibrillation
threshold resulted to be 4.8 ± 2.7 joule [68].
The possibility to include in an electrical defibrillator
a drug delivery system able to deliver a bolus of an
antiarrhyhtmic drug in order to painless terminate AF is
currently under evaluation [65].
Catheter ablation
Two different approaches can be used in patients with
AF using radiofrequency catheter ablation: 1) atrio-
ventricular (AV) junction ablation or AV node
modification for rate control in patients with chronic
persistent AF; 2) ablation of the atrial substrate by
creating linear lesions in the right and/or the left atrium
or by ablating atrial foci in cases of AF of focal origin
[18, 81, 82]. Atrio-ventricular junction ablation
combined with pacemaker insertion is a purely palliative
treatment [26, 82]; however, it is a safe and effective
procedure to be used in poorly tolerated chronic
permanent AF with high ventricular rate. With these
selected indications, this procedure may have a
favourable cost-benefit. Its use in paroxysmal AF need
to be limited, in our view, to very selected cases.
Atrioventricular node modification is aimed to reduce
ventricular rate during AF avoiding pacemaker
implantation. Effective modification of AV node can be
obtained in 65-75% of patients but inadvertent complete
heart block may occur in up to 16% of patients at the
time of the procedure or later during the follow-up [26].
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The possibility to cure AF by catheter ablation has
created a growing enthusiasm. The first application of
radiofrequency catheter ablation was related to the creation
of linear barriers to prevent intra-atrial reentry and to reply
surgical Maze procedure. Different techniques were used
[81] (right atrial and/or left atrial linear ablation) with a
rate of acute success ranging from 33% to 100% and a
rate of long-term success ranging from 33% to 80%. The
difficulties in performing the procedure, the evidence of
procedure-related complications and the need for
technological improvements in catheter and mapping
techniques [83] have limited the possibility to consider
this procedure as a therapeutic option to be adopted in
daily clinical practice.
Haissaguerre et al. [18] on the basis of elegant
mapping of the pulmonary veins demonstrated the
importance of the regions around and inside the
pulmonary veins for initiating and maintaining AF. These
observations led to focal ablation of pulmonary veins
foci as a curative treatment for AF. Indeed, in selected
cases of AF without underlying heart disease, a focal
origin of AF was described by Haissaguerre et al. [18],
more frequently at the origin of left pulmonary veins.
These Authors showed that ablation of atrial foci was
able to cure AF in 62% of treated patients. At present
time it is not known how many patients with lone AF
have this kind of focal substrate.
The frequent existence of multiple foci and the
problem of pulmonary veins stenosis inspired an
alternative approach [83]. This approach is based on non-
fluoroscopic electroanatomic mapping with creation, by
radiofrequency, of circumferential lines of conduction
block around the ostia of each pulmonary vein.
Combined or hybrid treatments
The awareness of the limitations of pharmacological
treatment led in recent years to the development of a
wide spectrum of electrical, non pharmacological
treatments [26]. Despite a series of limitations, non
pharmacological techniques may convey significant
advantages to AF treatment in appropriately selected
groups of patients. However, up to now, a single
procedure able to cure drug refractory AF in a large
percentage of patients with the best guaranties for safety
and efficacy could not be identified.
The limitations, in terms of efficacy rate, of AF
management based on a single treatment has led to the
concept of combined or hybrid treatments (Table 4). The
rationale of combined or hybrid treatments is to combine
different therapeutic modalities in an attempt to achieve a
synergetic effect, to improve efficacy over single
approaches by acting on different targets (the
electrophysiological substrate, the anatomical substrate,
the triggers, the modulating factors), having also a rescue
treatment in case of failure (Table 5). In view of the
potential effects on different targets (AF terminations,
atrial conduction and refractoriness, atrial premature
beats frequency, atrial electrophysiological remodeling,
Table 4. - Possible combined or hybrid therapies that
can be used in selected cases of drug-refractory AF
AA drugs + atrial pacing (at interatrial septum/ biatrial/ dual site)
AA drugs + atrial pacing + algorithms to suppress PAC
AA drugs + atrial pacing + algorithms to suppress PAC
   + atrial defibrillator
AA drugs + atrial ablation
AA drugs + atrial pacing + atrial ablation
AF: atrial fibrillation; AA drugs: antiarrhythmic drugs; PAC: premature
atrial complexes.
Table 5.  - Rationale for hybrid treatments: ability of different treatments to modify a series of variables facilitating AF
initiation/maintenance
AF termination Atrial conduction PAC frequency Reversal of Atrial size
and refractoriness electrophysiological
remodeling
Antiarrhythmic drugs + + + + + / ? -
Atrial pacing - / ? + + ? -
Internal cardioversion + + - - + / ? + / ?
Focal ablation + / - + + / - ? + +
Linear ablation + / - + + / - ? + +
AF: atrial fibrillation; PAC: premature atrial complexes; +: clinically relevant effect; ++: strong clinical effect; - : lack of clinical effect;
?: unknown effect.
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atrial size) a series of treatments (antiarrhythmic drugs,
internal cardioversion, atrial pacing with/without specific
pacing algorithms, focal ablation, linear ablation) may
be combined with the aim to achieve a synergetic effect
(Tables 4 and 5).
This approach is therefore justified by two
expectations: 1) some of non pharmacological treatments
may render AF responsive to previously ineffective
drugs; and 2) the combined use of more than one non
pharmacological treatment is expected to be required,
alone or in combination to drugs, in some patients, in
order to obtain a synergetic effect [84, 85].
Prospective studies are required to evaluated the risk-
benefit profile of these strategies in appropriately
selected patients [26, 84, 85].
Conclusions. The role of electrophysiological
approaches in AF treatment
At present the approach to AF treatment is guided
by a careful analysis of the electrophysiological patterns
of AF (on the basis of multiple intra-atrial recordings or
sophisticated new mapping techniques) only in a
restricted minority of patients, those who are candidates
to ablation of the substrate and/or the triggers.
Indeed, AF has a broad spectrum of clinical
presentations and a heterogeneous electrophysiological
pattern and its treatment, both with drugs and non
pharmacological treatments, has been based, classically,
on empiric basis and on a clinically-guided staged-
approach. The limitations of pharmacological treatments
led in recent years to the development of a wide spectrum
of electrical, non pharmacological treatments. This
implies a change in the approach to AF and the need to
identify potentially ideal candidates to complex and
expensive treatments.
It is matter of investigation to evaluate if the analysis
of the electrophysiological pattern may be helpful for
identifying a priori potential responders to a definitive
treatment or a combination of treatments (both
pharmacological and non-pharmacological). This
approach could be advantageous both in term of risk-
benefit ratio and cost-effectiveness but requires a series
of controlled trials to be validated and a standardisation
of mapping techniques coupled with further advances
into the knowledge of AF electrophysiology.
Submitted on invitation.
Accepted on 29 March 2001.
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